Plain-English translation of NCT06514547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This research study is testing how well a pneumococcal vaccine protects people living with HIV, compared to people without HIV, at different ages. Researchers will give all participants a pneumococcal vaccine and then track their immune system's response through blood tests over two years. The goal is to understand whether HIV and aging together make it harder for vaccines to work, so doctors can develop better vaccination strategies for older people living with HIV.
People living with HIV often develop chronic inflammation that weakens their immune system, and this problem may get worse with age. Currently, doctors don't have enough information about how well vaccines work in older people with HIV, so this study aims to fill that gap and help improve vaccine recommendations for this group.
You likely qualify if…
You likely don't qualify if…
You will receive a pneumococcal vaccine at your first visit, and then return for blood draws at specific time points over the course of two years—with intensive testing at 30 days after vaccination, and then ongoing monitoring throughout the study period. Each visit involves a blood draw so researchers can measure how well your immune system is responding to the vaccine. The study involves four different groups of participants (older and younger people, both with and without HIV) so that researchers can compare vaccine responses across these groups.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Hennepin Healthcare Research Institute
Collaborators
National Institute on Aging (NIA)
Enrollment target
~250 participants
Started
July 2024
Primary completion
September 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anne Frosch, MD
Hennepin Healthcare Research Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.